Claris receives ANDA approval for Bupivacaine Injection

Claris Lifesciences along with its subsidiaries (Claris) has received the Abbreviated New Drug Application (ANDA) approval for Bupivacaine Hydrochloride in 8.25% Dextrose Injection USP, 7.5 mg/mL, Single-dose Ampules with 2ml fill volumes, in the United States of America (US).

With this approval, Claris now has a total of 15 approvals and 25 under approval ANDAs, the total addressable market size of the approved ANDAs is estimated to be a little above $300 million. The company expects more product approvals during the year, which will allow it to continue its growth in the US market.

Bupivacaine Hydroxhloride in Dextorse Injection is a local or regional anesthesia used as a long-acting anesthetic during surgical procedures.